nach oben

Erschienen in:

23.03.2021 | Original Article

Correlation between serum cysteine-rich protein 61 and disease activity of antineutrophil cytoplasmic antibody–associated vasculitis

verfasst von: Taejun Yoon, Sung Soo Ahn, Jung Yoon Pyo, Lucy Eunju Lee, Jason Jungsik Song, Yong-Beom Park, Sang-Won Lee

Erschienen in: Clinical Rheumatology | Ausgabe 9/2021

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Cysteine-rich protein 61 (CYR61) stimulates protein kinase B (Akt)–mediated nuclear factor-kappa B (NF-κB) signalling leading to an increase in pro-inflammatory cytokines, which play important roles in the pathogenesis of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV). Hence, we investigated whether serum CYR61 was correlated with disease activity of AAV in a single-centre prospective cohort.

Methods

Seventy-two patients with AAV were randomly selected and included. Serum CYR61, interleukin (IL)-6 and IL-8 levels were quantified with the patients’ stored sera, and clinical and laboratory data at the time of blood sampling were collected. Spearman’s correlation and linear regression analysis was conducted to analyse the correlation between continuous variables. The optimal cut-off of serum CYR61 for predicting high disease activity was identified using the receiver operator characteristic curve. Birmingham vasculitis activity score (BVAS) was used as a measure to assess disease activity, and high disease activity was defined as BVAS ≥ 12.

Results

Serum CYR61 significantly correlated with BVAS (r = 0.249), erythrocyte sedimentation rate (r = 0.283), C-reactive protein (r = 0.298) and serum IL-6 (r = 0.319). However, a linear association was not found between CYR61 and BVAS (β = 0.102, P = 0.304). The relative risk (RR) for high disease activity in AAV patients with serum CYR61 ≥ 236.2 pg/mL was higher than those with serum CYR61 < 236.2 pg/mL (RR 3.316, P = 0.018).

Conclusion

Even though serum CYR61 was not directly proportional to the increase of BVAS, it could be predictive of high disease activity in AAV.

Key Points

• Serum CYR61 was significantly correlated with BVAS along with ESR, CRP and serum IL-6.

• The cut-off of serum CYR61 for high disease activity of AAV was obtained as 236.2 pg/mL.

• AAV patients with serum CYR61 ≥ 236.2 pg/mL had increased risk of having higher disease activity than those with serum CYR61 < 236.2 pg/mL (RR 3.316, P = 0.018).

Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CG, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone JH, Takahashi K, Watts RA (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65(1):1–11. https://doi.org/10.1002/art.37715CrossRefPubMed

Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, Mahr A, Segelmark M, Cohen-Tervaert JW, Scott D (2007) Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66(2):222–227. https://doi.org/10.1136/ard.2006.054593CrossRefPubMed

Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, Flossmann O, Hall C, Hollywood J, Jayne D, Jones R, Lanyon P, Muir A, Scott D, Young L, Luqmani RA (2009) Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 68(12):1827–1832. https://doi.org/10.1136/ard.2008.101279CrossRefPubMed

Kim MK, Choi H, Kim JY, Song JJ, Park YB, Lee SW (2020) Multivariable index for assessing the activity and predicting all-cause mortality in antineutrophil cytoplasmic antibody-associated vasculitis. J Clin Lab Anal 34(1):e23022. https://doi.org/10.1002/jcla.23022CrossRefPubMed

Park HJ, Jung SM, Song JJ, Park YB, Lee SW (2018) Platelet to lymphocyte ratio is associated with the current activity of ANCA-associated vasculitis at diagnosis: a retrospective monocentric study. Rheumatol Int 38(10):1865–1871. https://doi.org/10.1007/s00296-018-4125-yCrossRefPubMed

Ahn SS, Jung SM, Song JJ, Park YB, Lee SW (2018) Neutrophil to lymphocyte ratio at diagnosis can estimate vasculitis activity and poor prognosis in patients with ANCA-associated vasculitis: a retrospective study. BMC Nephrol 19(1):187. https://doi.org/10.1186/s12882-018-0992-4CrossRefPubMedPubMedCentral

Shi J, Huo R, Li N, Li H, Zhai T, Li H, Shen B, Ye J, Fu R, Di W (2019) CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress. BMC Cancer 19(1):1140. https://doi.org/10.1186/s12885-019-6321-xCrossRefPubMedPubMedCentral

Sun Y, Zhang J, Zhou Z, Wu P, Huo R, Wang B, Shen Z, Li H, Zhai T, Shen B, Chen X, Li N (2015) CCN1, a pro-inflammatory factor, aggravates psoriasis skin lesions by promoting keratinocyte activation. J Invest Dermatol 135(11):2666–2675. https://doi.org/10.1038/jid.2015.231CrossRefPubMed

Lin J, Zhou Z, Huo R, Xiao L, Ouyang G, Wang L, Sun Y, Shen B, Li D, Li N (2012) Cyr61 induces IL-6 production by fibroblast-like synoviocytes promoting Th17 differentiation in rheumatoid arthritis. J Immunol 188(11):5776–5784. https://doi.org/10.4049/jimmunol.1103201CrossRefPubMed

10.

O’Brien EC, Abdulahad WH, Rutgers A, Huitema MG, O’Reilly VP, Coughlan AM, Harrington M, Heeringa P, Little MA, Hickey FB (2015) Intermediate monocytes in ANCA vasculitis: increased surface expression of ANCA autoantigens and IL-1β secretion in response to anti-MPO antibodies. Sci Rep 5:11888. https://doi.org/10.1038/srep11888CrossRefPubMedPubMedCentral

11.

Berti A, Cavalli G, Campochiaro C, Guglielmi B, Baldissera E, Cappio S, Sabbadini MG, Doglioni C, Dagna L (2015) Interleukin-6 in ANCA-associated vasculitis: rationale for successful treatment with tocilizumab. Semin Arthritis Rheum 45(1):48–54. https://doi.org/10.1016/j.semarthrit.2015.02.002CrossRefPubMed

12.

Jennette JC, Falk RJ (2014) Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nat Rev Rheumatol 10(8):463–473. https://doi.org/10.1038/nrrheum.2014.103CrossRefPubMed

13.

Han CW, Lee EJ, Iwaya T, Kataoka H, Kohzuki M (2004) Development of the Korean version of Short-Form 36-Item Health Survey: health related QOL of healthy elderly people and elderly patients in Korea. Tohoku J Exp Med 203(3):189–194. https://doi.org/10.1620/tjem.203.189CrossRefPubMed

14.

Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin P, French Vasculitis Study Group (FVSG) (2011) The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 90(1):19–27. https://doi.org/10.1097/MD.0b013e318205a4c6CrossRef

15.

Bhamra K, Luqmani R (2012) Damage assessment in ANCA-associated vasculitis. Curr Rheumatol Rep 14(6):494–500. https://doi.org/10.1007/s11926-012-0291-1CrossRefPubMed

16.

Fang F, Shangguan AJ, Kelly K, Wei J, Gruner K, Ye B, Wang W, Bhattacharyya S, Hinchcliff ME, Tourtellotte WG, Varga J (2013) Early growth response 3 (Egr-3) is induced by transforming growth factor-β and regulates fibrogenic responses. Am J Pathol 183(4):1197–1208. https://doi.org/10.1016/j.ajpath.2013.06.016CrossRefPubMedPubMedCentral

17.

Wieland GD, Nehmann N, Müller D, Eibel H, Siebenlist U, Sühnel J, Zipfel PF, Skerka C (2005) Early growth response proteins EGR-4 and EGR-3 interact with immune inflammatory mediators NF-kappaB p50 and p65. J Cell Sci 118(Pt 14):3203–3212. https://doi.org/10.1242/jcs.02445CrossRefPubMed

18.

Sun Y, Zhang J, Zhai T, Li H, Li H, Huo R, Shen B, Wang B, Chen X, Li N, Teng J (2017) CCN1 promotes IL-1β production in keratinocytes by activating p38 MAPK signaling in psoriasis. Sci Rep 7:43310. https://doi.org/10.1038/srep43310CrossRefPubMedPubMedCentral

19.

Zhu X, Xiao L, Huo R, Zhang J, Lin J, Xie J, Sun S, He Y, Sun Y, Zhou Z, Shen B, Li N (2013) Cyr61 is involved in neutrophil infiltration in joints by inducing IL-8 production by fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Res Ther 15(6):R187. https://doi.org/10.1186/ar4377CrossRefPubMedPubMedCentral

20.

Tashiro M, Sasatomi Y, Watanabe R, Watanabe M, Miyake K, Abe Y, Yasuno T, Ito K, Ueki N, Hamauchi A, Noda R, Hisano S, Nakashima H (2016) IL-1β promotes tubulointerstitial injury in MPO-ANCA-associated glomerulonephritis. Clin Nephrol 86(10):190–199. https://doi.org/10.5414/CN108902CrossRefPubMed

21.

Lee KH, Kronbichler A, Park DD, Park Y, Moon H, Kim H, Choi JH, Choi Y, Shim S, Lyu IS, Yun BH, Han Y, Lee D, Lee SY, Yoo BH, Lee KH, Kim TL, Kim H, Shim JS, Nam W, So H, Choi S, Lee S, Shin JI (2017) Neutrophil extracellular traps (NETs) in autoimmune diseases: a comprehensive review. Autoimmun Rev 16(11):1160–1173. https://doi.org/10.1016/j.autrev.2017.09.012CrossRefPubMed

22.

Lin J, Li N, Chen H, Liu C, Yang B, Ou Q (2015) Serum Cyr61 is associated with clinical disease activity and inflammation in patients with systemic lupus erythematosus. Medicine (Baltimore) 94(19):e834. https://doi.org/10.1097/MD.0000000000000834CrossRef

23.

Fan Y, Yang X, Zhao J, Sun X, Xie W, Huang Y, Li G, Hao Y, Zhang Z (2019) Cysteine-rich 61 (Cyr61): a biomarker reflecting disease activity in rheumatoid arthritis. Arthritis Res Ther 21(1):123. https://doi.org/10.1186/s13075-019-1906-yCrossRefPubMedPubMedCentral

24.

Su Y, Wang Z, Ye J, Feng T, Wang F, Chi H, Zhou Z, Hu Q, Liu H, Cheng X, Shi H, Teng J, Yang C, Sun Y (2019) Cysteine-rich angiogenic inducer 61 serves as a potential serum biomarker for the remission of adult-onset still’s disease. Front Med (Lausanne) 6:266. https://doi.org/10.3389/fmed.2019.00266CrossRef

25.

Choi JS, Kim KH, Lau LF (2015) The matricellular protein CCN1 promotes mucosal healing in murine colitis through IL-6. Mucosal Immunol 8(6):1285–1296. https://doi.org/10.1038/mi.2015.19CrossRefPubMedPubMedCentral

26.

Choy EH, De Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T (2020) Translating IL-6 biology into effective treatments. Nat Rev Rheumatol 16(6):335–345. https://doi.org/10.1038/s41584-020-0419-zCrossRefPubMed

27.

Tackey E, Lipsky PE, Illei GG (2004) Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 13(5):339–343. https://doi.org/10.1191/0961203304lu1023oaCrossRefPubMedPubMedCentral

28.

Kallenberg CG (2015) Pathogenesis and treatment of ANCA-associated vasculitides. Clin Exp Rheumatol 33(4 Suppl 92):S11–S14PubMed

Titel: Correlation between serum cysteine-rich protein 61 and disease activity of antineutrophil cytoplasmic antibody–associated vasculitis
verfasst von: Taejun Yoon
Sung Soo Ahn
Jung Yoon Pyo
Lucy Eunju Lee
Jason Jungsik Song
Yong-Beom Park
Sang-Won Lee
Publikationsdatum: 23.03.2021
Verlag: Springer International Publishing
Erschienen in: Clinical Rheumatology / Ausgabe 9/2021
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-021-05701-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Correlation between serum cysteine-rich protein 61 and disease activity of antineutrophil cytoplasmic antibody–associated vasculitis